Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

h and development 906 (2) - - 904 Other expense/(income), net 134 - - - 134 Special and acquisition-related charges 94 - (94) - - Equity income (493) - - 64 (429) ----- - - -- ----- Income before income taxes 502 357 94 (64) 889 Income tax expense/(benefit) 40 (73) (7) - 120 -- ---- --- - --- Net income $462 $284 $87 $(64) $769 ---- ---- === ---- ---- Preferred stock dividends 38 - - - 38 -- - - - -- Net income available to common shareholders $424 $284 $87 $(64) $731 ==== ==== === ==== ==== Diluted earnings per common share $0.26 $0.45 ===== ===== Average shares outstanding common and participating - diluted 1,632 1,632 (1) "As Reconciled" to exclude purchase accounting adjustments, special and acquisition-related items and other specified items.


    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
(Date:9/30/2014)... Fla. , Sept. 30, 2014 CORD:USE ... pleased to announce that it has entered into an ... Inc. (Tianhe) which has licensed a series of patented technologies ... cells for possible clinical applications.  Tianhe is performing Phase ... and Spain using Tianhe,s Stem ...
(Date:9/30/2014)... September 30, 2014 OriginOil Inc. (OTC/QB: ... chemical-free process to clean up large quantities of water, ... Riggs Eckelberry reported on the launch of the company's ... site provided by partner STW Resources . , ... barrels per day (bpd) and achieved a 99.8% reduction ...
(Date:9/30/2014)... DEL MAR, Calif. , Sept. 30, 2014 /PRNewswire/ ... devices for women,s health announces its receipt of a ... The FemmyCycle menstrual cup has also received FDA clearance ... Health Canada, and the CE in Europe. This patent is ... design. In conjunction with this issuance, the company is releasing ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2The FemmyCycle 2
... Emmy® and Tony® award-winning actress Blythe Danner and Amgen ... Reduce Fractures™, an educational campaign for women with postmenopausal ... Danner was diagnosed with postmenopausal osteoporosis at increased risk ... to educate themselves, take action and speak to their ...
... August 25, 2011 Amsterdam Molecular Therapeutics (Euronext: ... today reported its results for the first half year of ... , Glybera®: , Data showing Glybera produces significant reduction ... Atherosclerosis Society Meeting CHMP does not consider Glybera ...
... Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused ... (CTCs) in cancer patients, and Clarient, Inc. (a GE ... of a proprietary blood test for CTCs in breast ...  Clarient and Biocept will market and sell Biocept,s new ...
Cached Biology Technology:Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 2Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 3Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 4Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 5Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 6Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 7Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 2Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 3Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 4Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 5Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 6Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 7Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 8Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 2Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 3Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 4
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
(Date:9/29/2014)... DC September 29, 2014 -- Plants have ... bacteria help the pants extract nutrients and defend ... pathogens from contaminating fruits and vegetables. Now, scientist ... bacteria inside of seeds; thus ensuring that sprouting ... from the University of Notre Dame, presented their ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... the past three decades, saturated fat has been considered a major ... persists in recommending reduced consumption of this macronutrient. However, new ... impact on CVD risk -- causing many to rethink the "saturated ... articles published in the October issue of Lipids ...
... New York, 1 October, 2010 A special article ... the recent Report of the 2010 Dietary Guidelines Advisory Committee ... to conform to the standards of evidence-based medicine, despite its ... The authors call the DGAC to task for failing to ...
... protein, STIM1, known to activate store-operated calcium channels has ... to researchers at Temple University. The researchers published ... Orai and Cav1.2 Channels, in the Oct. 1 issue ... Calcium, not just important for bones and teeth, is ...
Cached Biology News:Think saturated fat contributes to heart disease? Think again 2Think saturated fat contributes to heart disease? Think again 3Proposed dietary guidelines for Americans sharply debated 2Protein provides link between calcium signaling in excitable and non-excitable cells 2
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
Biology Products: